Literature DB >> 25881716

Phenoconversion and therapeutic drug monitoring.

Jose de Leon1,2,3.   

Abstract

Keywords:  clobazam; clozapine; genotype-phenotype mismatch; personalized medicine; pharmacogenetics; risperidone; therapeutic drug monitoring; venlafaxine

Mesh：

Substances：

Year:  2015        PMID： 25881716      PMCID： PMC4594716          DOI： 10.1111/bcp.12659

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

Review 1.  A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II.

Authors:  Jose de Leon; Neil B Sandson; Kelly L Cozza
Journal:  Psychosomatics       Date:  2008 Jul-Aug       Impact factor: 2.386

Review 2.  Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.

Authors:  S Crettol; J de Leon; C Hiemke; C B Eap
Journal:  Clin Pharmacol Ther       Date:  2013-11-06       Impact factor: 6.875

3.  A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

Authors:  J A Bork; T Rogers; P J Wedlund; J de Leon
Journal:  J Clin Psychiatry       Date:  1999-07       Impact factor: 4.384

Review 4.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

Review 5.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

6.  Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.

Authors:  Sheldon H Preskorn; Cecelia P Kane; Kasia Lobello; Alice I Nichols; Rana Fayyad; Gina Buckley; Kristen Focht; Christine J Guico-Pabia
Journal:  J Clin Psychiatry       Date:  2013-03-13       Impact factor: 4.384

Review 7.  Pharmacokinetics and drug interactions: update for new antipsychotics.

Authors:  L Ereshefsky
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

Review 8.  The future (or lack of future) of personalized prescription in psychiatry.

Authors:  Jose de Leon
Journal:  Pharmacol Res       Date:  2008-10-17       Impact factor: 7.658

Review 9.  Clinical applications of CYP genotyping in psychiatry.

Authors:  Edoardo Spina; Jose de Leon
Journal:  J Neural Transm (Vienna)       Date:  2014-09-09       Impact factor: 3.575

10.  A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

Authors:  J de Leon; M T Susce; R-M Pan; P J Wedlund; M L Orrego; F J Diaz
Journal:  Pharmacopsychiatry       Date:  2007-05       Impact factor: 5.788
  10 in total
  5 in total

1.  Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.

Authors:  Ádám Kiss; Ádám Menus; Katalin Tóth; Máté Déri; Dávid Sirok; Evelyn Gabri; Ales Belic; Gábor Csukly; István Bitter; Katalin Monostory
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-02       Impact factor: 5.270

Review 2.  Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics.

Authors:  Andrea Gaedigk; Jean C Dinh; Hyunyoung Jeong; Bhagwat Prasad; J Steven Leeder
Journal:  J Pers Med       Date:  2018-04-17

3.  Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients.

Authors:  Jing Zhu; Tejendra Patel; Jordan A Miller; Chad D Torrice; Mehak Aggarwal; Margaret R Sketch; Maurice D Alexander; Paul M Armistead; James M Coghill; Tatjana Grgic; Katarzyna J Jamieson; Jonathan R Ptachcinski; Marcie L Riches; Jonathan S Serody; John L Schmitz; J Ryan Shaw; Thomas C Shea; Oscar Suzuki; Benjamin G Vincent; William A Wood; Kamakshi V Rao; Tim Wiltshire; Eric T Weimer; Daniel J Crona
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

Review 4.  Impact of New Genomic Technologies on Understanding Adverse Drug Reactions.

Authors:  Simran D S Maggo; Ruth L Savage; Martin A Kennedy
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

Review 5.  Moderators and mediators of antipsychotic response in delusional disorder: Further steps are needed.

Authors:  Alexandre González-Rodríguez; Armand Guàrdia; Diego José Palao; Javier Labad; Mary V Seeman
Journal:  World J Psychiatry       Date:  2020-04-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.